trending Market Intelligence /marketintelligence/en/news-insights/trending/Y_Rx64GCof0Vs_3LGlEjzQ2 content esgSubNav
In This List

Omeros, Endo reach settlement over eye drug

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Omeros, Endo reach settlement over eye drug

Endo International plc reached a settlement agreement with Omeros Corp., agreeing not to launch a generic version of the Omidria eye drug before April 1, 2032.

Omeros sued the company after it filed an application seeking approval from the U.S. Food and Drug Administration to market a generic version of the medicine.

Omeros said the abbreviated new drug application infringed on its patents covering Omidria.

Endo acknowledged the validity of the patents and also agreed to pay a 15% royalty on the sales of its generic drug once it enters the market up until the last of the patents covering Omidria expires Oct. 23, 2033.